NEWS HIGHLIGHTSMedia Articles Related to Oxyir (Oxycodone)
The Opioid Crisis and Need for Compassion in Pain Management Source: Medscape Anesthesiology Headlines [2017.09.28] In this commentary, the author expresses concern that the response to the public health crisis of opioid addiction is creating a growing crisis of inadequate pain management. American Journal of Public Health
CVS to Restrict Opioid Painkiller Prescription Amounts Source: MedicineNet Drug Abuse Specialty [2017.09.25] Title: CVS to Restrict Opioid Painkiller Prescription Amounts Category: Health News Created: 9/22/2017 12:00:00 AM Last Editorial Review: 9/25/2017 12:00:00 AM
Stomach Pain Quiz: Nausea & Other Causes Source: MedicineNet Anal Fissure Specialty [2017.09.19] Title: Stomach Pain Quiz: Nausea & Other Causes Category: MedicineNet Quiz Created: 1/20/2011 12:00:00 AM Last Editorial Review: 9/19/2017 5:59:56 PM
Back Pain Quiz: Test Your Back Pain IQ Source: MedicineNet Ankylosing Spondylitis Specialty [2017.09.19] Title: Back Pain Quiz: Test Your Back Pain IQ Category: MedicineNet Quiz Created: 6/16/2011 3:41:00 PM Last Editorial Review: 9/19/2017 6:39:04 PM
Pain Quiz: Test Your IQ of Pain Source: MedicineNet Constipation Specialty [2017.09.19] Title: Pain Quiz: Test Your IQ of Pain Category: MedicineNet Quiz Created: 7/14/2011 3:53:00 PM Last Editorial Review: 9/19/2017 6:41:41 PM
Published Studies Related to Oxyir (Oxycodone)
Comparison of subjective effects of extended-release versus immediate-release
oxycodone/acetaminophen tablets in healthy nondependent recreational users of
prescription opioids: a randomized trial. [2014] [APAP]) formulation with those of immediate-release (IR) OC/APAP... CONCLUSIONS: Extended-release OC/APAP produced lower subjective drug effects than
A randomized, double-blind, placebo-controlled study of oral oxycodone plus
acetaminophen for the treatment of pain in photodynamic therapy on port wine
stains. [2014] efficacy and safety of an oral analgesic for the treatment of pain in PDT on PWS... CONCLUSIONS: The time of the pain beginning was 8.31 ± 4.58 min in
Safety and efficacy of once-daily hydromorphone extended-release versus
twice-daily oxycodone hydrochloride controlled-release in chinese patients with
cancer pain: a phase 3, randomized, double-blind, multicenter study. [2014] Noninferiority of the efficacy of once-daily hydromorphone hydrochloride
extended-release (hydromorphone ER) compared with twice-daily oxycodone
hydrochloride controlled-release (oxycodone CR) was investigated in this
randomized, double-blind study in Chinese patients with moderate to severe cancer
pain requiring strong oral opioid analgesics.
Oral oxycodone plus intravenous acetaminophen versus intravenous morphine sulfate
in acute bone fracture pain control: a double-blind placebo-controlled randomized
clinical trial. [2014] control efforts efficacy and decrease the adverse effects of each medication... CONCLUSION: Intravenous acetaminophen plus oral oxycodone is as effective as
Bowel function after tapentadol and oxycodone immediate release (IR) treatment in
patients with low back or osteoarthritis pain. [2013] OBJECTIVES: Constipation is a common side effect of opioid therapy. Tapentadol
immediate release (IR) was better tolerated than oxycodone IR in 2 clinical
trials involving patients with low back or osteoarthritis pain... DISCUSSION: Patient-reported bowel function associated with tapentadol IR
treatment was similar to that associated with placebo (10-d trial) and
significantly better than that associated with oxycodone IR treatment (10- and
90-d trials).
Clinical Trials Related to Oxyir (Oxycodone)
Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia [Not yet recruiting]
Cystectomy with urinary diversion (ileal conduit, ileal orthotopic neobladder,
catheterizable ileal pouch) is major abdominal surgery, which is associated with a high
incidence of gastrointestinal complications. Perioperative techniques aiming at an early
return of bowel function are to be pursued.
Optimal postoperative pain management is one of the key factors leading to enhanced recovery
after surgery. The perioperative use of an epidural analgesia for major abdominal surgery is
established, not only because of its excellent analgesic properties, but also because it can
accelerate the return of bowel function. However, epidural analgesia is associated with
additional costs, need for close monitoring and nursing. In addition each supplemental day
with an indwelling epidural catheter increases the risk of infection. So it is recommended
to re-assess the risk/benefit ratio of an epidural analgesia after 4 days, if not sooner.
Therefore, it is important to develop strategies that reduce its duration without impairing
the benefits. Systemic analgesics with prolonged-release oral formulation like oral
oxycodone (Oxycontin®) or combined drug mixture (oral oxycodone/naloxone (Targin®)) could be
a valuable alternative pain treatment as a second analgesic step, starting on postoperative
day (POD) 3, so that the epidural catheter could be removed earlier without impairing
postoperative enhanced recovery including return of the bowel function. Both oxycodone and
naloxone orally administered are a recognized and accepted treatment option.
The objective of this study is to evaluate the implementation of an oral opioid with or
without naloxone in the early postoperative period in patients undergoing open radical
cystectomy with urinary diversion and intraoperative and early postoperative use of epidural
analgesia. The investigators expect an unchanged early return of the bowel function and
equal analgesia with a reduced length of stay of the epidural catheter (primary endpoint),
thus potentially reducing epidural catheter associated complications and lowering costs
(nursing and pain service).
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone [Completed]
Pharmacokinetics Study of ALO-02 and OxyContin [Completed]
To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the
administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice
Daily in Healthy Volunteers
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans [Completed]
Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the
dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there
is potential for off label use in chronic pain.
Tapentadol is a new molecular entity that is structurally similar to tramadol. Tapentadol
is a centrally-acting analgesic with a dual mode of action as an agonist at the mu-opioid
receptor and as a norepinephrine reuptake inhibitor. These two actions are synergistic in
pain relief. While its action reflects aspects of tramadol and morphine, its ability to
control pain is more on the order of hydrocodone and oxycodone.
Its dual mode of action provides analgesia at similar levels of more potent narcotic
analgesics such as hydrocodone, oxycodone, and meperidine with a more tolerable side effect
profile. Clinical studies showed that tapentadol effectively relieves moderate to severe
pain in various pain care settings. In addition, it was reported to be associated with
significantly fewer treatment discontinuations due to a significantly lower incidence of
gastrointestinal-related adverse events compared with equivalent doses of oxycodone. The
combination of these reduced treatment discontinuation rates and tapentadol efficacy for the
relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in
pain therapy by increasing patient compliance with their treatment regimen.
Abuse Liability of Controlled-Release Oxycodone Formulations [Completed]
The objective of this study is to examine the abuse liability of a single 40mg dose of 2
controlled release oxycodone formulations (Apo-Oxycodone CR® and OxyNEO®) in non-dependent
recreational opioid users by assessing the self-reported acute effects of the drugs and
taking blood samples to measure drug concentrations. The investigators think there may be
differences in how well these drugs are liked when swallowed whole due to differences in how
the products are formulated.
|